ME02896B - Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4 - Google Patents
Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4Info
- Publication number
- ME02896B ME02896B MEP-2017-238A MEP2017238A ME02896B ME 02896 B ME02896 B ME 02896B ME P2017238 A MEP2017238 A ME P2017238A ME 02896 B ME02896 B ME 02896B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- methyl
- pharmaceutically acceptable
- salt
- acceptable salt
- Prior art date
Links
- IMLAIXAZMVDRGA-UHFFFAOYSA-N 2-phenoxyethanamine Chemical class NCCOC1=CC=CC=C1 IMLAIXAZMVDRGA-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (12)
1. Spoj formule: , naznačen time što X je: , , , , , , , ili ; R je H, metil ili etil; R1 je metil, kada je R2 H, a R1 je H kada je R2 metil; R3 je H ili F; R4 je H, F ili metil; R5 je OH, metil, metoksi ili F; R6 je H kada je R7 OH, a R6 je F kada je R7 F; i svaki od R8 i R9 je neovisno H ili F; ili njegova farmaceutski prihvatljiva sol.
2. Spoj ili sol u skladu s patentnim zahtjevom 1, naznačen time što je R metil.
3. Spoj ili sol u skladu s bilo patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je R4 F, a R5 je F.
4. Spoj ili sol u skladu s bilo patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je R4 metil, a R5 je metil.
5. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je R8 F, a R9 je F.
6. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je X: , , , , ili .
7. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je X: , ili .
8. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 7, naznačen time što je namijenjen upotrebi u terapiji.
9. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 7, naznačen time što je namijenjen upotrebi u liječenju osteoartritisa.
10. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 7, naznačen time što je namijenjen upotrebi u liječenju reumatoidnog artritisa.
11. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevima 1 do 7, naznačen time što je namijenjen upotrebi u liječenju boli povezane s osteoartritisom ili reumatoidnim artritisom.
12. Farmaceutski pripravak, naznačen time što sadrži spoj, ili njegovu farmaceutski prihvatljivu sol, u skladu s patentnim zahtjevima 1 do 7, uz jednu ili više farmaceutski prihvatljivih podloga, razrjeđivača ili pomoćnih tvari.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916827P | 2013-12-17 | 2013-12-17 | |
| EP14827907.8A EP3083562B1 (en) | 2013-12-17 | 2014-12-11 | Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators |
| PCT/US2014/069743 WO2015094902A1 (en) | 2013-12-17 | 2014-12-11 | Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02896B true ME02896B (me) | 2018-04-20 |
Family
ID=52355185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-238A ME02896B (me) | 2013-12-17 | 2014-12-11 | Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9776964B2 (me) |
| EP (1) | EP3083562B1 (me) |
| JP (1) | JP6212644B2 (me) |
| KR (1) | KR101807981B1 (me) |
| CN (1) | CN105793242B (me) |
| AU (1) | AU2014366361B2 (me) |
| BR (1) | BR112016011016A8 (me) |
| CA (1) | CA2928593A1 (me) |
| CY (1) | CY1119583T1 (me) |
| DK (1) | DK3083562T3 (me) |
| EA (1) | EA028921B1 (me) |
| ES (1) | ES2651858T3 (me) |
| HR (1) | HRP20171850T1 (me) |
| HU (1) | HUE035698T2 (me) |
| LT (1) | LT3083562T (me) |
| ME (1) | ME02896B (me) |
| MX (1) | MX2016007566A (me) |
| NO (1) | NO3221486T3 (me) |
| PL (1) | PL3083562T3 (me) |
| PT (1) | PT3083562T (me) |
| RS (1) | RS56615B1 (me) |
| SI (1) | SI3083562T1 (me) |
| WO (1) | WO2015094902A1 (me) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| US11712438B2 (en) | 2017-05-18 | 2023-08-01 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as PGE2 receptor modulators |
| TW201900179A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物 |
| PT3625228T (pt) | 2017-05-18 | 2021-09-16 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores dos recetores de pge2 |
| AR111874A1 (es) | 2017-05-18 | 2019-08-28 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
| MA49127B1 (fr) | 2017-05-18 | 2022-05-31 | Idorsia Pharmaceuticals Ltd | Dérivés d'indole n-substitués |
| CN109970625B (zh) * | 2017-12-28 | 2021-02-26 | 新发药业有限公司 | 一种5r-苄氧氨基哌啶-2s-甲酸或其衍生物的制备方法 |
| WO2020251957A1 (en) * | 2019-06-11 | 2020-12-17 | Teon Therapeutics, Inc. | Prostaglandin e2 receptor 4 antagonists and uses thereof |
| EP3885339A1 (en) * | 2020-03-27 | 2021-09-29 | Rottapharm Biotech S.r.l. | Process for the preparation of (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof |
| KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
| CN112608271A (zh) * | 2020-11-26 | 2021-04-06 | 安润医药科技（苏州）有限公司 | 酰胺衍生物及其在制备ep4受体拮抗剂中的应用 |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
| CN117164507A (zh) * | 2023-05-26 | 2023-12-05 | 康化（上海）新药研发有限公司 | 一种阿加曲班杂质(2r,4r)-4-甲基-2-哌啶甲酸的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2500157C2 (de) | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung |
| JP2005531516A (ja) | 2002-03-18 | 2005-10-20 | ファイザー・プロダクツ・インク | 選択的ｅｐ４受容体アゴニストによる治療方法 |
| ES2313079T3 (es) * | 2003-07-28 | 2009-03-01 | Janssen Pharmaceutica Nv | Benzimidazol, benzotiazol, benzoxazol y su utilizacion como moduladores de lta4h. |
| JP4116058B2 (ja) | 2003-09-03 | 2008-07-09 | ファイザー株式会社 | プロスタグランジンｅ２拮抗薬としてのフェニルまたはピリジルアミド化合物 |
| CN1950333A (zh) * | 2004-05-04 | 2007-04-18 | 辉瑞大药厂 | 取代的甲基芳基或杂芳基酰胺化合物 |
| CN1950334A (zh) | 2004-05-04 | 2007-04-18 | 辉瑞有限公司 | 邻位取代的芳基或杂芳基酰胺化合物 |
| US7968578B2 (en) | 2006-04-24 | 2011-06-28 | Merck Frosst Canada Ltd. | Indole amide derivatives as EP4 receptor antagonists |
| JP5183628B2 (ja) | 2006-06-12 | 2013-04-17 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのインドリンアミド誘導体 |
| EP2172447A4 (en) * | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
| CN102026961B (zh) * | 2008-05-14 | 2014-04-09 | 安斯泰来制药株式会社 | 酰胺化合物 |
| CN102149384B (zh) | 2008-08-14 | 2014-08-20 | 南京奥昭生物科技有限公司 | 作为ep4受体拮抗剂的杂环酰胺衍生物 |
| ES2600355T3 (es) | 2010-02-22 | 2017-02-08 | Raqualia Pharma Inc. | Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis |
| DK2729445T3 (en) * | 2011-07-04 | 2016-01-18 | Rottapharm Biotech Srl | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS |
| EP2729141B1 (en) | 2011-07-04 | 2015-12-09 | Rottapharm Biotech S.r.l. | Cyclic amine derivatives as ep4 receptor agonists |
| JO3296B1 (ar) | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) * | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
-
2014
- 2014-12-11 JP JP2016538744A patent/JP6212644B2/ja not_active Expired - Fee Related
- 2014-12-11 ES ES14827907.8T patent/ES2651858T3/es active Active
- 2014-12-11 EP EP14827907.8A patent/EP3083562B1/en active Active
- 2014-12-11 KR KR1020167015741A patent/KR101807981B1/ko not_active Expired - Fee Related
- 2014-12-11 BR BR112016011016A patent/BR112016011016A8/pt not_active IP Right Cessation
- 2014-12-11 WO PCT/US2014/069743 patent/WO2015094902A1/en not_active Ceased
- 2014-12-11 SI SI201430434T patent/SI3083562T1/sl unknown
- 2014-12-11 RS RS20171227A patent/RS56615B1/sr unknown
- 2014-12-11 HU HUE14827907A patent/HUE035698T2/en unknown
- 2014-12-11 LT LTEP14827907.8T patent/LT3083562T/lt unknown
- 2014-12-11 DK DK14827907.8T patent/DK3083562T3/da active
- 2014-12-11 CN CN201480068170.1A patent/CN105793242B/zh not_active Expired - Fee Related
- 2014-12-11 EA EA201690894A patent/EA028921B1/ru not_active IP Right Cessation
- 2014-12-11 PT PT148279078T patent/PT3083562T/pt unknown
- 2014-12-11 HR HRP20171850TT patent/HRP20171850T1/hr unknown
- 2014-12-11 PL PL14827907T patent/PL3083562T3/pl unknown
- 2014-12-11 CA CA2928593A patent/CA2928593A1/en not_active Abandoned
- 2014-12-11 MX MX2016007566A patent/MX2016007566A/es unknown
- 2014-12-11 US US15/030,888 patent/US9776964B2/en not_active Expired - Fee Related
- 2014-12-11 ME MEP-2017-238A patent/ME02896B/me unknown
- 2014-12-11 AU AU2014366361A patent/AU2014366361B2/en not_active Ceased
-
2015
- 2015-10-02 NO NO15775410A patent/NO3221486T3/no unknown
-
2017
- 2017-11-09 CY CY20171101176T patent/CY1119583T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6212644B2 (ja) | 2017-10-11 |
| AU2014366361B2 (en) | 2017-04-20 |
| HUE035698T2 (en) | 2018-05-28 |
| EA028921B1 (ru) | 2018-01-31 |
| EP3083562A1 (en) | 2016-10-26 |
| CN105793242A (zh) | 2016-07-20 |
| MX2016007566A (es) | 2016-10-03 |
| KR101807981B1 (ko) | 2017-12-11 |
| ES2651858T3 (es) | 2018-01-30 |
| PL3083562T3 (pl) | 2018-02-28 |
| PT3083562T (pt) | 2017-12-13 |
| DK3083562T3 (da) | 2017-11-13 |
| NO3221486T3 (me) | 2018-09-08 |
| CY1119583T1 (el) | 2018-03-07 |
| SI3083562T1 (sl) | 2017-11-30 |
| JP2016540007A (ja) | 2016-12-22 |
| KR20160084467A (ko) | 2016-07-13 |
| EP3083562B1 (en) | 2017-09-27 |
| RS56615B1 (sr) | 2018-02-28 |
| CN105793242B (zh) | 2018-02-16 |
| WO2015094902A1 (en) | 2015-06-25 |
| HRP20171850T1 (hr) | 2018-01-12 |
| CA2928593A1 (en) | 2015-06-25 |
| BR112016011016A8 (pt) | 2018-01-30 |
| US9776964B2 (en) | 2017-10-03 |
| AU2014366361A1 (en) | 2016-05-19 |
| US20160272585A1 (en) | 2016-09-22 |
| LT3083562T (lt) | 2018-01-10 |
| EA201690894A1 (ru) | 2016-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02896B (me) | Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4 | |
| HRP20171515T1 (hr) | Spojevi fenoksietilpiperidina | |
| ME02910B (me) | Spojevi tetrahidropirolotiazina | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| BR112012026951A2 (pt) | Compostos de amino-piridazinas úteis na modulação da contratilidade do músculo esquelético, composições farmacêuticas e uso dos compostos | |
| EA201492050A1 (ru) | Модуляторы ядерного транспорта и их применение | |
| HRP20250250T1 (hr) | Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji | |
| MX373716B (es) | Compuesto de pirazol-amida y sus usos farmaceuticos. | |
| EP3939572C0 (en) | CARRIER SUBSTANCE FOR THE CONTROLLED RELEASE OF VARIOUS PHARMACEUTICAL ACTIVE INGREDIENTS | |
| HRP20150770T1 (hr) | Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin | |
| EA201791239A8 (ru) | ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ | |
| MY174188A (en) | Heterocyclyl compounds | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| EA201690044A1 (ru) | Модуляторы ядерного транспорта и их применение | |
| HRP20161103T1 (hr) | Kemijski spojevi | |
| NZ612000A (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
| ME02576B (me) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| BR112014005407A2 (pt) | composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv | |
| ME02566B (me) | Derivati imidazopiridazina kao modulatori receptora gabaa | |
| BR112015013485A2 (pt) | derivados de benzilsulfonamida como moduladores de rorc | |
| ME02655B (me) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
| ME02405B (me) | Spojevi pirazola као inhibitori sglt1 | |
| MX380619B (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| ME02107B (me) | Heteroaril jedinjenja kao ligandi 5-ht4 receptora |